Market Performance Overview
On Friday, the 23rd of October 2026, Mindwalk (ticker HYFT) experienced a modest decline, closing 1.55 % lower at 05:34 AM Central Europe time. The share price settled around USD 1.20 on the Nasdaq, reflecting a continued downward trend that has extended to 14.19 % over the past month.
The company’s market capitalization stands at USD 60.8 million, with a daily trading volume of approximately USD 144 thousand. Its 200‑day simple moving average (SMA) is USD 1.44, placing the current price slightly below this long‑term benchmark. The most recent peak for Mindwalk was USD 2.99, recorded on January 12, 2026, while its 52‑week low was USD 0.99 on March 30, 2026.
With a share supply of 47.1 million, the market cap to supply ratio indicates a moderate valuation relative to peers in the biotechnology sector.
Comparative Performance of Peer Stocks
The short‑term movement of Mindwalk sits within a broader context of volatility in the biopharmaceutical segment. Over the same 24‑hour period, the following related stocks reported the following changes:
| Company | Ticker | % Change | Current Price (USD) | Market Capitalisation (USD) | P/E Ratio |
|---|---|---|---|---|---|
| Cognition Therapeutics | CGTX | +1.77 % | 0.70 | 71.2 million | – |
| Spero Therapeutics | SPRO | –4.10 % | 1.13 | 71.1 million | 9.62 |
| Air T | AIRT | –1.06 % | 26.15 | 71.0 million | 1.13 |
| Lensar | LNSR | –2.07 % | 6.02 | 71.4 million | 11.02 |
| Nutriband | NTRB | +4.96 % | 5.81 | 71.1 million | – |
While Cognition Therapeutics and Nutriband exhibited positive movement, Spero Therapeutics, Air T, and Lensar trended lower, mirroring the downward pressure seen in Mindwalk. These fluctuations suggest that investor sentiment across the sector remains cautious, likely influenced by recent regulatory reviews and clinical trial timelines.
Company Profile
ImmunoPrecise Antibodies Ltd., the entity behind the HYFT ticker, is a Canadian healthcare firm headquartered in Toronto. The company focuses on the development and production of therapeutic antibodies, offering services such as monoclonal and polyclonal antibody development, cryopreservation, and hybridoma licensing. Its product line targets a range of therapeutic indications, including oncology and autoimmune diseases.
ImmunoPrecise’s operations are primarily domestic, serving the Canadian market, and the company maintains an active presence on the Nasdaq exchange. For further details regarding its product pipeline, research partnerships, and corporate governance, stakeholders may consult the company’s website at www.immunoprecise.com .
